Pronota Is to Receive Patent on Biomarker for Diagnosing Renal Failure in the US Despite Prometheus
Ghent, Belgium (ots/PRNewswire) - The United States Patent and Trade Office (USPTO) has allowed Pronota's patent for the use of a blood-based biomarker LG3 in the decision-making process for the treatment of renal dysfunction. This is a major step forward for Pronota as it reconfirms the patentability of the use of ...
plus